A research team led by ChBE Gillespie Professor Ted Randolph, John Carpenter (CU School of Pharmacy), and the CU-based company BaroFold, Inc. has been awarded a patent for improving protein-based drug formulations used to treat cancers, infectious diseases and several other diseases. The invention reduces sub-visible particles that can cause adverse immune responses in the patient.
Other inventors on the patent are ChBE doctoral graduates Amber (Haynes) Fradkin and Matthew Seefeldt (now president of BaroFold).
The patent (U.S. 8,697,848, “Method for Reducing Immunogenicity of Therapeutic Protein Compositions”) was issued on April 15, 2014, with a related patent application pending in the U.S. and patent protection also being sought in Europe and Canada. Prosecution for this patent family began in July 2010.